Photo/VCG

1.OpenAI releases user-customized ChatGPT

OpenAI released a number of new tools at its first developer conference, "OpenAI DevDay." OpenAI now allows users to build custom versions of ChatGPT without coding. OpenAI also plans to launch a store similar to Apple's App Store later this month, sharing revenue with creators.

2.SpaceX's revenue is expected to reach $15 billion next year

According to foreign media reports, SpaceX's revenue from rocket launches and Starlink services is expected to reach about $90 billion this year, and sales are expected to reach about $15 billion by 2024. As Starlink is launched in more regions around the world, the product's sales are expected to exceed SpaceX's rocket business next year. At that time, Starlink will account for most of SpaceX's revenue.

3.Breakthrough in room-temperature manipulation of quantum photofluids

According to a paper published in the latest issue of Physical Review Letters, a team of physicists from the Skolkovo Institute of Science and Technology in Russia has made progress in the spatial manipulation and energy control of room-temperature quantum photofluids (also known as polarization condensates). This marks an important milestone in the development of high-speed, all-optical polarization logic devices. These devices have long been key to next-generation non-conventional computing.

4. German AI startup raises over $500 million in new round of funding

German AI startup Aleph Alpha GmbH announced on its website that it has raised over $500 million in total investment in its Series B round. Aleph Alpha has positioned itself as a leader in European AI technology, equivalent to "Germany's own OpenAI." 

6. New generation of "AlphaFold" from Google's DeepMind

According to foreign media reports, Google's DeepMind recently released a new generation of AI tool for predicting protein structure, "AlphaFold-latest." Not only has the accuracy been significantly improved, but the prediction range has also expanded from proteins to other biological molecules, including ligands. The model will be used in drug design to help quickly and accurately describe the structures of a variety of large molecules that are very important for treating diseases.

7. Eli Lilly's Chief Scientist: Major Breakthrough in Alzheimer's Disease on the Horizon

Daniel Skovronsky, chief scientist of Eli Lilly, the world's highest-valued pharmaceutical company, has expressed "extreme optimism" that a major breakthrough in Alzheimer's disease is on the horizon. According to trial data, Eli Lilly's investigational drug donanemab can not only slow the progression of the disease, but also potentially prevent the onset of Alzheimer's disease.